PDSB PDS Biotechnology Corporation
Price Chart
Executive Summary
PDS Biotech reported Q1 2026 net loss of $7.3M ($0.13/share), narrower than the $8.5M loss ($0.21/share) in Q1 2025, driven by lower R&D and G&A expenses. The EPS of -$0.13 beat the consensus estimate of -$0.14 by 7.1%, but the company remains a pre-revenue clinical-stage biotech with no approved products and a cash runway of $21.7M. The key catalyst is the amended VERSATILE-003 Phase 3 trial protocol incorporating PFS as an interim endpoint, which could enable an accelerated approval pathway for PDS0101 in head and neck cancer.
Actionable Insight
The EPS beat and cost reduction are positive, but the stock's movement will hinge on clinical catalysts—specifically the amended VERSATILE-003 protocol and any FDA feedback on accelerated approval. Monitor the 8:00 am ET investor webcast for updates on trial enrollment restart and regulatory interactions. The $21.7M cash position provides runway into mid-2027 at current burn rate, but dilution risk remains high given the pre-revenue stage.
Key Facts
- Q1 2026 net loss of $7.3M ($0.13/share) vs $8.5M ($0.21/share) in Q1 2025
- EPS of -$0.13 beat consensus estimate of -$0.14 by 7.1%
- Cash balance of $21.7M as of March 31, 2026, down from $26.7M at year-end 2025
- Amended VERSATILE-003 Phase 3 trial to include PFS as interim primary endpoint, potentially enabling accelerated approval for PDS0101
- Positive mCRC data published in JCO: 77.8% ORR at 6 months and ~85% 24-month survival rate with PDS01ADC combination
- R&D expenses decreased to $3.5M from $5.8M YoY due to lower clinical and manufacturing costs
- Accumulated deficit of $224M; total stockholders' equity of $3.9M
Financial Impact
Q1 2026 net loss improved by $1.2M YoY; cash burn of ~$5M in the quarter; no revenue generated
Risk Factors
- Pre-revenue biotech with no approved products; entirely dependent on clinical trial success
- Cash burn of ~$5M/quarter; $21.7M cash provides limited runway without additional financing
- VERSATILE-003 trial amendment may face FDA pushback on accelerated approval pathway
- High dilution risk: weighted average shares outstanding increased 37% YoY to 55.5M
- Accumulated deficit of $224M with no near-term revenue prospects
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3293836 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 2, 2026
7d ago
|
8-K
| $1.16 $1.08 | ▼ −6.90% | ▼ −6.20% | $1.03 (−11.21%) |
|
May 13, 2026
27d ago
|
Press Release
| $1.33 $1.43 | ▲ +7.52% | ▲ +6.74% | $1.03 (−22.56%) |
|
May 1, 2026
5w ago
|
8-K
| $0.9810 $1.00 | ▼ −1.94% | ▼ −2.28% | $1.03 (−4.99%) |
|
Apr 27, 2026
6w ago
|
S-3/A
| $0.9300 $1.08 | ▲ +16.13% | ▲ +16.61% | $1.03 (+10.75%) |
|
Apr 24, 2026
6w ago
|
8-K
| $0.9300 $1.08 | ▲ +16.13% | ▲ +16.61% | $1.03 (+10.75%) |
|
Apr 15, 2026
7w ago
|
8-K
| $1.36 $1.28 | ▼ −5.88% | ▼ −6.14% | $1.03 (−24.26%) |
|
Apr 15, 2026
7w ago
|
Press Release
| $1.36 $1.28 | ▼ −5.88% | ▼ −6.14% | $1.03 (−24.26%) |
|
Mar 30, 2026
10w ago
|
Press Release
| $0.5370 $0.6050 | ▲ +12.66% | ▲ +9.77% | $1.03 (+91.81%) |
|
Mar 24, 2026
11w ago
|
Press Release
| $0.6350 $0.6400 | ▲ +0.79% | ▲ +2.56% | $1.03 (+62.20%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access